The Food and Drug Administration (=FDA) approved medications available for Relapsing Forms of Multiple Sclerosis except for Mitoxantrone and Ocrevus that are approved for progressive MS:

Injectables:

Glatiramer Acetate (Copaxone) – Daily injections under the skin (=subcutaneously); approved 1996-1997

Interferon Beta 1b = Betaseron – Every other day injection subcutaneously; approved 1993

Interferon Beta 1b = Extavia – Every other day injection subcutaneously; identical to Betaseron

Interferon Beta 1a = Avonex – Weekly intramuscular (into the muscle) injection; approved 1996

Interferon Beta 1a = Rebif – Three times a week injections usually done Monday-Wednesday-Friday subcutaneously; approved in 2002 in USA

Long acting interferon Beta 1a=Plegridy – Subcutaneously injection every 14 days 

Intravenous Medication:

Natalizumab = Tysabri – Intravenous medication given every 28 days; approved 2005-2006

Novantrone = Mitoxantrone – Intravenous medication given every 3 months; approved in 2001; not used due to cardiotoxcity

Alemtuzumab = Lemtrada – infusion x 5 days during the first year and then 2nd year x 3 days & then based on counts

Ocrelizumab=Ocrevus – initial two doses are 300 mg each separated by two weeks, then Ocrevus 600 mg six months after the initial two doses. Approved 3/28/2017

Oral Medications:

Fingolimod = Gilenya – once a day oral medication recommended to be taken every morning; approved in 2010

Teriflunomide = Aubagio – once a day oral medication; approved in 2012

BG-12 = Dimethyl Fumarate=Tecfidera – Twice a day oral medication recommended to be taken with meals (breakfast & dinner); approved in 2013